GlassScriptPhysician profile
Ashley M Matter
NPI 1568967834
$723.61
in general payments reported to CMS, 2019-2025
12 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $256 · 2024: $153 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $135.39 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $106.19 | 2023-2025 | Gemtesa, Myfembree |
| Pfizer INC. | $101.87 | 2022-2025 | |
| Astellas Pharma US INC | $98.81 | 2025 | Veozah |
| Exeltis, USA INC. | $81.24 | 2022-2023 | Slynd |
| Axonics, INC. | $37.12 | 2024 | Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $33.87 | 2024 | |
| Solventum Corporation | $32.44 | 2025 | V.A.C. Veraflo, Activ.A.C., Prevena |
| Organon LLC | $30.63 | 2022-2024 | |
| Myovant Sciences INC. | $27.23 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $23.82 | 2023 | Exparel |
| Kci USA, INC. | $15.00 | 2023 | Activ.A.C., Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Matter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.